Geneseeq Technology Inc.

Geneseeq is a research-driven company providing cutting-edge next-generation sequencing (NGS) technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type-specific gene panels for all sample types to help match a patient to the optimal treatment, including targeted therapy and immunotherapy for solid tumors and blood cancers. Additionally, we develop cutting-edge technologies and kits for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Our testing services are conducted in our CAP/CLIA/ISO15189-accredited laboratory, where we manufacture IVD and RUO testing kits for in-house solutions. With a global reach, our headquarters are located in both Canada and China. Our products and services are well-established and ordered by over 8,000 long-term oncologist partners across 12+ countries and regions. We are engaged in 2,200+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We work closely with our partners to address their specific needs, maintaining a relentless focus on quality and efficiency.